Real-world corticosteroid use in severe pneumonia: a propensity-score-matched study

dc.contributor.authorCeccato, Adrian
dc.contributor.authorRusso, A.
dc.contributor.authorBarbeta, Enric
dc.contributor.authorOscanoa, Patricia
dc.contributor.authorTiseo, Giusy
dc.contributor.authorGabarrús, Albert
dc.contributor.authorDi Giannatale, Pierluigi
dc.contributor.authorNogas, Stefano
dc.contributor.authorCillóniz, Catia
dc.contributor.authorMenichetti, F.
dc.contributor.authorFerrer Monreal, Miquel
dc.contributor.authorNiederman, Michael S.
dc.contributor.authorFalcone, Marco
dc.contributor.authorTorres Martí, Antoni
dc.date.accessioned2022-05-23T17:45:33Z
dc.date.available2022-05-23T17:45:33Z
dc.date.issued2021-12-16
dc.date.updated2022-05-23T17:45:33Z
dc.description.abstractBackground: Community-acquired pneumonia (CAP) is a leading cause of morbidity and mortality worldwide despite correct antibiotic use. Corticosteroids have long been evaluated as a treatment option, but heterogeneous efects on survival have precluded their widespread implementation. We aimed to evaluate whether corticosteroids might improve clinical outcomes in patients with severe CAP and high infammatory responses. Study design and methods: We analyzed two prospective observational cohorts of patients with CAP in Barcelona and Rome who were admitted to intensive care with a high infammatory response. Propensity score (PS) matching was used to obtain balance among the baseline variables in both groups, and we excluded patients with viral pneumonia or who received hydrocortisone. Results: Of the 610 patients admitted with severe CAP, 198 (32%) received corticosteroids and 387 had major criteria for severe CAP. All patients had a baseline serum C-reactive protein above 15 mg/dL. Patients who received corticosteroids were more commonly male, had more comorbidities (e.g., cancer or chronic obstructive pulmonary disease), and presented with signifcantly higher sequential organ failure assessment scores. Eighty-nine patients met major severity criteria (invasive mechanical ventilation and/or septic shock) and were matched per group. Twenty-eightday mortality was lower among patients receiving corticosteroids (16 patients, 18%) than among those not receiving them (28 patients, 31%; p=0.037). After PS matching, corticosteroid therapy reduced the 28-day mortality risk in patients who met major severity criteria (hazard ratio (HR) 0.53, 95% confdence interval (CI) 0.29-0.98) (p=0.043). In patients who did not meet major severity criteria, no benefts were observed with corticosteroid use (HR 0.88 (95%CI 0.32-2.36). Conclusions: Corticosteroid treatment may be of beneft for patients with CAP who have septic shock and/or a high infammatory response and requirement for invasive mechanical ventilation. Corticosteroids appear to have no impact on mortality when these features are not present.
dc.format.extent7 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec721205
dc.identifier.issn1364-8535
dc.identifier.pmid34915895
dc.identifier.urihttps://hdl.handle.net/2445/185931
dc.language.isoeng
dc.publisherBioMed Central
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1186/s13054-021-03840-x
dc.relation.ispartofCritical Care, 2021, vol. 25, num. 1, p. 432-438
dc.relation.urihttps://doi.org/10.1186/s13054-021-03840-x
dc.rightscc-by (c) Ceccato, Adrian et al., 2021
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourceArticles publicats en revistes (Medicina)
dc.subject.classificationPneumònia adquirida a la comunitat
dc.subject.classificationMortalitat
dc.subject.classificationCorticosteroides
dc.subject.classificationAssaigs clínics
dc.subject.classificationSepticèmia
dc.subject.otherCommunity-acquired pneumonia
dc.subject.otherMortality
dc.subject.otherAdrenocortical hormones
dc.subject.otherClinical trials
dc.subject.otherSepticemia
dc.titleReal-world corticosteroid use in severe pneumonia: a propensity-score-matched study
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
721205.pdf
Mida:
956.42 KB
Format:
Adobe Portable Document Format